Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis

Fibrosis is an underlying cause of cirrhosis and hepatic failure resulting in end stage liver disease with limited pharmacological options. The beneficial effects of relaxin peptide treatment were demonstrated in clinically relevant animal models of liver fibrosis. However, the use of relaxin is pro...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:FASEB J
Glavni autori: Kaftanovskaya, Elena M., Ng, Hooi Hooi, Soula, Mariluz, Rivas, Bryan, Myhr, Courtney, Ho, Brian A., Cervantes, Briana A., Shupe, Thomas D., Devarasetty, Mahesh, Hu, Xin, Xu, Xin, Patnaik, Samarjit, Wilson, Kenneth J., Barnaeva, Elena, Ferrer, Marc, Southall, Noel T., Marugan, Juan J., Bishop, Colin E., Agoulnik, Irina U., Agoulnik, Alexander I.
Format: Artigo
Jezik:Inglês
Izdano: Federation of American Societies for Experimental Biology 2019
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6988856/
https://ncbi.nlm.nih.gov/pubmed/31419161
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1096/fj.201901046R
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items